Vaxil has all data tested already on patients !!!!Positive interim results from phase I/II multiple myeloma cancer vaccine trial antigen that is present in 90% of all tumors. The patient’s immune system is trained to identify and destroy cancer cells where the MUC1 marker is present. The cancer vaccine ImMucin, developed by Vaxil, was identified using the company`s proprietary technology VaxHit. It is a peptide vaccine derived from a unique sequence contained in the MUC1 tumor-associated The Israeli clinical stage biotechnology company Vaxil BioTherapeutics has released positive interim results from its phase I/II therapeutic cancer vaccine trial in multiple myeloma patients.
They have tested their patents on patients already , just for some Morons on this site !!!!
And they will apply this to Coronavirus patients now!!!
I